The third question relates to the question of page 3 of the regulatory impact statement, which is around the benefits. Firstly, there's been no financial data on this at all. How much is it going to cost and how much is it going to benefit? There's a pretty standard equation in a regulatory impact statement. We know there are more than 800,000 doses expected to be administered once the bill passes. What is the cost of that administration for both vaccine and the fees to the people who will be administering them? And then at the bottom of page 3 it talks about the benefit, which is basically a reduction in the risk of infection and severity of the illnesses—approximately two to four times less likely for those aged between 60 and 100 years, and a 78 percent lower mortality rate from COVID than those who only received a third dose. I wonder what the research was. How much is that in quantity of the reduction in harm? That's usually pretty easily able to be measured by QALYS, or quality-adjusted life years, or some other kind of metric. And did any analysis take into account the fact that many of those people would not only have had three doses but would've also had COVID and therefore by dint of that would've had a boosted natural immunity, which may have the same effect as a fourth dose? That, for me, I think, actually underscores why the World Health Organization were pretty equivocal about the benefits of the fourth dose.